SDZNY Quote, Financials, Valuation and Earnings

CRISPR Therapeutics AG has a net margin of -39.83% compared to Sandoz Group AG's net margin of -106.6%. Sandoz Group AG's return on equity of -- beat CRISPR Therapeutics AG's return on equity of -18.65%.

Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.67 which suggests that it could grow by 96.69%. Given that CRISPR Therapeutics AG has higher upside potential than Sandoz Group AG, analysts believe CRISPR Therapeutics AG is more attractive than Sandoz Group AG.

Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.751, suggesting its more volatile than the S&P 500 by 75.105%.

Sandoz Group AG has a quarterly dividend of $0.73 per share corresponding to a yield of 1.4%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

Sandoz Group AG quarterly revenues are $74.4M, which are larger than CRISPR Therapeutics AG quarterly revenues of $35M. Sandoz Group AG's net income of -$29.6M is higher than CRISPR Therapeutics AG's net income of -$136M. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 2.17x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -39.83% compared to Sandoz Group AG's net margin of 26.48%. Sandoz Group AG's return on equity of -- beat Novartis AG's return on equity of 30.96%.

Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Novartis AG has an analysts' consensus of $112.64 which suggests that it could fall by -4.6%. Given that Novartis AG has higher upside potential than Sandoz Group AG, analysts believe Novartis AG is more attractive than Sandoz Group AG.

Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.595, suggesting its less volatile than the S&P 500 by 40.528%.

Sandoz Group AG has a quarterly dividend of $0.73 per share corresponding to a yield of 1.4%. Novartis AG offers a yield of 3.38% to investors and pays a quarterly dividend of $3.99 per share. Sandoz Group AG pays -- of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sandoz Group AG quarterly revenues are $74.4M, which are smaller than Novartis AG quarterly revenues of $13.6B. Sandoz Group AG's net income of -$29.6M is lower than Novartis AG's net income of $3.6B. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while Novartis AG's PE ratio is 18.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 2.17x versus 4.47x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

BeOne Medicines has a net margin of -39.83% compared to Sandoz Group AG's net margin of 0.11%. Sandoz Group AG's return on equity of -- beat BeOne Medicines's return on equity of -11.54%.

Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines has an analysts' consensus of $331.97 which suggests that it could grow by 26.51%. Given that BeOne Medicines has higher upside potential than Sandoz Group AG, analysts believe BeOne Medicines is more attractive than Sandoz Group AG.

Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BeOne Medicines has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.143%.

Sandoz Group AG has a quarterly dividend of $0.73 per share corresponding to a yield of 1.4%. BeOne Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -- of its earnings as a dividend. BeOne Medicines pays out -- of its earnings as a dividend.

Sandoz Group AG quarterly revenues are $74.4M, which are smaller than BeOne Medicines quarterly revenues of $1.1B. Sandoz Group AG's net income of -$29.6M is lower than BeOne Medicines's net income of $1.3M. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while BeOne Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 2.17x versus 6.74x for BeOne Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of -39.83% compared to Sandoz Group AG's net margin of --. Sandoz Group AG's return on equity of -- beat Roche Holding AG's return on equity of 23.8%.

Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Roche Holding AG has an analysts' consensus of $46.42 which suggests that it could grow by 12.96%. Given that Roche Holding AG has higher upside potential than Sandoz Group AG, analysts believe Roche Holding AG is more attractive than Sandoz Group AG.

Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.459, suggesting its less volatile than the S&P 500 by 54.134%.

Sandoz Group AG has a quarterly dividend of $0.73 per share corresponding to a yield of 1.4%. Roche Holding AG offers a yield of 3.38% to investors and pays a quarterly dividend of $1.39 per share. Sandoz Group AG pays -- of its earnings as a dividend. Roche Holding AG pays out 92.43% of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sandoz Group AG quarterly revenues are $74.4M, which are larger than Roche Holding AG quarterly revenues of --. Sandoz Group AG's net income of -$29.6M is higher than Roche Holding AG's net income of --. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while Roche Holding AG's PE ratio is 28.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 2.17x versus 3.76x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.